Protalix BioTherapeutics (PLX) Non-Current Deffered Revenue (2010 - 2022)

Protalix BioTherapeutics' Non-Current Deffered Revenue history runs 13 years deep, the most recent figure standing at $5.9 million for Q2 2022.

• On a quarterly basis, Non-Current Deffered Revenue rose 364.54% year-over-year to $5.9 million in Q2 2022; TTM through Jun 2022 was $5.9 million, a 364.54% increase from a year earlier, with the FY2021 full-year figure at $11.8 million, up 587.06% from the prior year.
• Non-Current Deffered Revenue held at $5.9 million in Q2 2022 per PLX's latest filing, from $5.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $34.9 million in Q2 2019 and bottomed at $858000.0 in Q1 2021.
• The 5-year median for Non-Current Deffered Revenue is $9.5 million (2020), against an average of $15.0 million.
• Across the five-year window, Non-Current Deffered Revenue sank 94.64% in 2020 and jumped 587.06% in 2021, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $33.0 million in 2018, then tumbled by 48.59% to $17.0 million in 2019, then plunged by 89.89% to $1.7 million in 2020, then soared by 587.06% to $11.8 million in 2021, then sank by 50.0% to $5.9 million in 2022.
• Per Business Quant, the three latest PLX Non-Current Deffered Revenue figures stand at $5.9 million (Q2 2022), $5.9 million (Q1 2022), and $11.8 million (Q4 2021).